JP7631358B2 - 吸入のためのｇｍ－ｃｓｆの液体製剤 - Google Patents

吸入のためのｇｍ－ｃｓｆの液体製剤 Download PDF

Info

Publication number
JP7631358B2
JP7631358B2 JP2022548034A JP2022548034A JP7631358B2 JP 7631358 B2 JP7631358 B2 JP 7631358B2 JP 2022548034 A JP2022548034 A JP 2022548034A JP 2022548034 A JP2022548034 A JP 2022548034A JP 7631358 B2 JP7631358 B2 JP 7631358B2
Authority
JP
Japan
Prior art keywords
liquid formulation
csf
rhgm
concentration
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517480A5 (enExample
JP2023517480A (ja
Inventor
スクリバー，ラース
ワット，アラン
Original Assignee
ドラッグリキュア エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドラッグリキュア エーピーエス filed Critical ドラッグリキュア エーピーエス
Publication of JP2023517480A publication Critical patent/JP2023517480A/ja
Publication of JP2023517480A5 publication Critical patent/JP2023517480A5/ja
Priority to JP2025017042A priority Critical patent/JP2025090573A/ja
Application granted granted Critical
Publication of JP7631358B2 publication Critical patent/JP7631358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022548034A 2020-03-17 2021-03-17 吸入のためのｇｍ－ｃｓｆの液体製剤 Active JP7631358B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017042A JP2025090573A (ja) 2020-03-17 2025-02-04 吸入のためのｇｍ－ｃｓｆの液体製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062990810P 2020-03-17 2020-03-17
US62/990,810 2020-03-17
EP20164648 2020-03-20
EP20164648.6 2020-03-20
PCT/EP2021/056851 WO2021185921A1 (en) 2020-03-17 2021-03-17 Liquid formulation of gm-csf for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017042A Division JP2025090573A (ja) 2020-03-17 2025-02-04 吸入のためのｇｍ－ｃｓｆの液体製剤

Publications (3)

Publication Number Publication Date
JP2023517480A JP2023517480A (ja) 2023-04-26
JP2023517480A5 JP2023517480A5 (enExample) 2024-03-21
JP7631358B2 true JP7631358B2 (ja) 2025-02-18

Family

ID=74871418

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548034A Active JP7631358B2 (ja) 2020-03-17 2021-03-17 吸入のためのｇｍ－ｃｓｆの液体製剤
JP2025017042A Pending JP2025090573A (ja) 2020-03-17 2025-02-04 吸入のためのｇｍ－ｃｓｆの液体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017042A Pending JP2025090573A (ja) 2020-03-17 2025-02-04 吸入のためのｇｍ－ｃｓｆの液体製剤

Country Status (12)

Country Link
US (1) US20230201307A1 (enExample)
EP (1) EP4121000A1 (enExample)
JP (2) JP7631358B2 (enExample)
KR (1) KR102874958B1 (enExample)
CN (1) CN115297844A (enExample)
AU (1) AU2021237761B2 (enExample)
BR (1) BR112022018501A2 (enExample)
CA (1) CA3168421A1 (enExample)
IL (1) IL295406A (enExample)
MX (1) MX2022011498A (enExample)
WO (1) WO2021185921A1 (enExample)
ZA (1) ZA202209002B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120324338A (zh) * 2025-06-10 2025-07-18 厦门特宝生物工程股份有限公司 一种重组人粒细胞巨噬细胞刺激因子注射用液体制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1739793A (zh) 2005-09-16 2006-03-01 深圳市孚沃德生物技术有限公司 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法
WO2007009208A1 (en) 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
WO2012021088A1 (en) 2010-08-13 2012-02-16 Closed Joint Stock Company "Biocad" A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020141970A1 (en) 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009208A1 (en) 2005-06-02 2007-01-25 Cangene Corporation Poly(ethylene glocol) modified human gm-csf with increased biological activity
CN1739793A (zh) 2005-09-16 2006-03-01 深圳市孚沃德生物技术有限公司 一种人粒细胞巨噬细胞集落刺激因子喷雾剂及其制备方法
WO2012021088A1 (en) 2010-08-13 2012-02-16 Closed Joint Stock Company "Biocad" A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation

Also Published As

Publication number Publication date
JP2025090573A (ja) 2025-06-17
WO2021185921A1 (en) 2021-09-23
BR112022018501A2 (pt) 2022-10-25
US20230201307A1 (en) 2023-06-29
CA3168421A1 (en) 2021-09-23
NZ791835A (en) 2025-10-31
AU2021237761B2 (en) 2026-02-05
CN115297844A (zh) 2022-11-04
KR102874958B1 (ko) 2025-10-21
KR20220154214A (ko) 2022-11-21
JP2023517480A (ja) 2023-04-26
IL295406A (en) 2022-10-01
MX2022011498A (es) 2022-10-07
EP4121000A1 (en) 2023-01-25
ZA202209002B (en) 2025-11-26
AU2021237761A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
Eedara et al. Spray-dried inhalable powder formulations of therapeutic proteins and peptides
EP0505123B1 (en) Pulmonary administration of granulocyte colony stimulating factor
CN100333790C (zh) 含白细胞介素－2的药物组合物在制药中的应用
US20220152145A1 (en) Method and formulation for inhalation
JP4338214B2 (ja) エリトロポエチンの肺投与
JP2549794B2 (ja) 肺投与用のシクロスポリン形態
CN102459327A (zh) 包含表面活性剂蛋白质b(sp-b)和表面活性剂蛋白质c(sp-c)的类似物的改良重构的表面活性剂组合物
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
JP2025090573A (ja) 吸入のためのｇｍ－ｃｓｆの液体製剤
WO2022143722A1 (zh) 吸入用药物组合物
US11365248B2 (en) Formulation of tocilizumab and method for treating COVID-19 by inhalation
TW201811311A (zh) 包含重組肺表面活性劑組成物之穩定醫藥配方
EA049666B1 (ru) Жидкий состав gm-csf для ингаляции
RU2410082C1 (ru) Цитокинсодержащая аэрозольная композиция
US20220323546A1 (en) Recombinant interferon
EP4493276A1 (en) Dosage forms of active substances used against viral diseases in dry powder inhaler device for symptoms caused by covid-19 and other viral lung diseases
WO1991016916A1 (fr) Agent antineoplastie

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221102

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150